Ardent Board Recharacterizes Former CEO Bonick's Exit as For-Cause, Clawing Back $4.5M Severance
ARDT sits 59% above its 52-week low of $7.71.
Summary
Ardent Health's board reclassified former CEO Martin Bonick's June 2026 separation as a termination for Cause, discontinuing about $4.5 million of unpaid cash severance and cancelling his unvested PRSUs after finding he failed to disclose third-party compensation. The company says no financial statements require restatement.
Key Events · Executive and Board Changes · ARDT
-
Board Reclassifies CEO Exit as For-Cause
On October 19, 2026 the board determined that facts discovered after the Separation Date would have supported terminating Martin J. Bonick for Cause as of June 2, 2026, and recharacterized his separation accordingly.
-
About $4.5M Severance Discontinued
The company will stop approximately $4.5 million of unpaid cash severance and cancel or forfeit all outstanding unvested performance-based restricted stock units.
-
Undisclosed Third-Party Compensation Cited
The board found Bonick failed to disclose fully to the board and company compensation received from third parties otherwise required to be reported under company policies.
-
No Financial Restatement Required
Ardent states none of its financial statements or previously disclosed results require revision or correction as a result of the findings.
Analysis · ARDT · Industrial Applications And Services
The board's conclusion that facts discovered after Martin Bonick's June 2, 2026 departure would have justified firing him for Cause has reclassified his exit, stopping roughly $4.5 million of unpaid cash severance and cancelling all unvested performance stock units. It found he failed to fully disclose third-party compensation required to be reported under company policy. Management says no financial statements need restating, which limits the accounting risk, though the company has reserved the right to pursue further remedies. This lands against a backdrop of already-damaged credibility: Q2 net income fell 77% to $16.9M, 2026 guidance was cut, and a prior revenue adjustment drew an SEC inquiry.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.2% of the 1549 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARDT was trading at $12.27 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $7.71 to $15.48. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.